MedTrace Logo

Effects of Quercetin on Cardiometabolic Outcomes

NCT06230861 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-27

No results posted yet for this study

Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Conditions

  • Cardiometabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Quercetin

Quercetin tablets 500mg 1 x per day

OTHER

Placebo

Placebo control 1 x blinded placebo tablet per day

Sponsors & Collaborators

  • DoNotAge.org

    collaborator INDUSTRY

  • University of Central Lancashire

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-08-01
Completion
2026-12-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06230861 on ClinicalTrials.gov